Clinical Sequential Topoisomerase Poisoning

Rubin, Eric H.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Small Research Grants (R03)
• Project #: 1R03CA071535-01
• Application #: 2115132
• Study Section: Special Emphasis Panel (SRC (O1))
• Project Start: 1996-08-08
• Project End: 1998-07-31
• Budget Start: 1996-08-08
• Budget End: 1997-07-31
• Support Year: 1
• Fiscal Year: 1996

Institution

• Name: University of Medicine & Dentistry of NJ
• Type: Organized Research Units
• DUNS #: 622146454
• City: Piscataway
• State: NJ
• Country: United States
• Zip Code: 08854

Publications

Saraiya, Biren; Gounder, Murugesan; Dutta, Jayeeta et al. (2008) Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs 19:411-20

Licitra, Edward J; Vyas, Viral; Nelson, Kathy et al. (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673-9

Saleem, A; Ibrahim, N; Patel, M et al. (1997) Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res 57:5100-6